|
F
A
P
M
| |
 |
  |
 |
 |
Ligand Pharmaceuticals
Incorporated discovers, develops and markets new drugs for critical unmet
medical needs of patients principally in the areas of cancer, skin diseases,
and hormone-related diseases. Ligand has five drugs approved for marketing
in the U.S. ¾
Targretin® (bexarotene) capsules, Targretin® (bexarotene)
gel 1%, ONTAK® (denileukin diftitox) and Panretin® (alitretinoin)
gel 0.1%. A fifth product, AVINZA® (morphine sulfate
extended-release capsules), was recently approved for marketing by the FDA
in the U.S. |
 
 |
Radionics is dedicated to helping physicians deliver minimally invasive
treatments to improve the quality of life of patients around the world.
We create precise, technologically superior products and provide the highest
quality of service and support.
Our mission is upheld by a unified team of professional caring employees. |
|
Faulding Laboratories develops, markets, and sells proprietary
pharmaceutical products and services designed to improve the quality of life
of patients and caregivers. Faulding Laboratories first product offering is
KADIAN (morphine sulfate sustained release) CII, which is proven to provide
24-hour control of chronic pain with the convenience of Once-a-Day or
Twice-a-Day dosing. |
 |
|
